METHODS: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.
RESULTS: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings.
CONCLUSIONS: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.
方法:参加亚洲治疗研究以评估耐药性-监测研究(TASER-S)的患者在开始ART之前进行基因分型,根据WHO2009年清单分析产生的耐药突变。
结果:来自TASER-S的最近感染个体的TDRM比例从0%到8.7%不等-香港:3/88(3.4%,95%CI(0.71%-9.64%);泰国:曼谷:13/277(4.7%,95%CI(2.5%-7.9%),清迈:0/17(0%,97.5%CI(0%-19.5%);菲律宾:6/69(8.7%,95%CI(3.3%-18.0%))。在所有四种临床设置中,TDRM随时间没有显著增加。
结论:来自香港的TASER-S患者中TDRM的观察比例,在研究期间,泰国和菲律宾的情况低到中等。应鼓励定期监测TDRM,特别是随着ART在更高的CD4水平上的扩大。